跳至主導覽 跳至搜尋 跳過主要內容

KIR/KIR-ligand genotypes and clinical outcomes following chemoimmunotherapy in patients with relapsed or refractory neuroblastoma: A report from the Children's Oncology Group

  • Amy K. Erbe*
  • , Mitch B. Diccianni
  • , Rajen Mody
  • , Arlene Naranjo
  • , Fan F. Zhang
  • , Jen Birstler
  • , Kyungmann Kim
  • , Arika S. Feils
  • , Jung Tung Hung
  • , Wendy B. London
  • , Barry L. Shulkin
  • , Varsha Mathew
  • , Marguerite T. Parisi
  • , Sabah Servaes
  • , Shahab Asgharzadeh
  • , John M. Maris
  • , Julie Park
  • , Alice L. Yu
  • , Paul M. Sondel
  • , Rochelle Bagatell
  • *此作品的通信作者
  • University of Wisconsin-Madison
  • University of California at San Diego
  • University of Michigan, Ann Arbor
  • University of Florida
  • CureSearch
  • Chang Gung Memorial Hospital
  • Dana-Farber Cancer Institute
  • St. Jude Children Research Hospital
  • Seattle Children's Hospital
  • The Children's Hospital of Philadelphia
  • Children's Hospital Los Angeles

研究成果: 期刊稿件 › 文章 › 同儕審查

19 引文 斯高帕斯(Scopus)

摘要

Background In the Children's Oncology Group ANBL1221 phase 2 trial for patients with first relapse/first declaration of refractory high-risk neuroblastoma, irinotecan and temozolomide (I/T) combined with either temsirolimus (TEMS) or immunotherapy (the anti-GD2 antibody dinutuximab (DIN) and granulocyte macrophage colony stimulating factory (GM-CSF)) was administered. The response rate among patients treated with I/T/DIN/GM-CSF in the initial cohort (n=17) was 53%; additional patients were enrolled to permit further evaluation of this chemoimmunotherapy regimen. Potential associations between immune-related biomarkers and clinical outcomes including response and survival were evaluated. Methods Patients were evaluated for specific immunogenotypes that influence natural killer (NK) cell activity, including killer immunoglobulin-like receptors (KIRs) and their ligands, Fc gamma receptors, and NCR3. Total white cells and leucocyte subsets were assessed via complete blood counts, and flow cytometry of peripheral blood mononuclear cells was performed to assess the potential association between immune cell subpopulations and surface marker expression and clinical outcomes. Appropriate statistical tests of association were performed. The Bonferroni correction for multiple comparisons was performed where indicated. Results Of the immunogenotypes assessed, the presence or absence of certain KIR and their ligands was associated with clinical outcomes in patients treated with chemoimmunotherapy rather than I/T/TEMS. While median values of CD161, CD56, and KIR differed in responders and non-responders, statistical significance was not maintained in logistic regression models. White cell and neutrophil counts were associated with differences in survival outcomes, however, increases in risk of event in patients assigned to chemoimmunotherapy were not clinically significant. Conclusions These findings are consistent with those of prior studies showing that KIR/KIR-ligand genotypes are associated with clinical outcomes following anti-GD2 immunotherapy in children with neuroblastoma. The current study confirms the importance of KIR/KIR-ligand genotype in the context of I/T/DIN/GM-CSF chemoimmunotherapy administered to patients with relapsed or refractory disease in a clinical trial. These results are important because this regimen is now widely used for treatment of patients at time of first relapse/first declaration of refractory disease. Efforts to assess the role of NK cells and genes that influence their function in response to immunotherapy are ongoing. Trial registration number NCT01767194.

原文英語
文章編號e006530
期刊Journal for ImmunoTherapy of Cancer
卷11
發行號2
DOIs
出版品狀態已出版 - 23 02 2023

文獻附註

© Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

UN SDG

此研究成果有助於以下永續發展目標

  1. SDG3 健康與福祉
    SDG3 健康與福祉

指紋

深入研究「KIR/KIR-ligand genotypes and clinical outcomes following chemoimmunotherapy in patients with relapsed or refractory neuroblastoma: A report from the Children's Oncology Group」主題。共同形成了獨特的指紋。

引用此